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A 69 year-old woman with a history of hyper-
tension, type 2 diabetes mellitus and chronic renal
insufficiency presented with generalized weakness
and near syncope. In the emergency room, she was
awake, alert and her physical examination was other-
wise unremarkable. She was bradycardic (45 bpm)
and hypotensive (85/55 mm Hg) and a 12-lead elec-
trocardiogram (ECG) showed third degree atrioven-
tricular (AV) block. Her medications at home includ-
ed verapamil (120 mg OD), hydralazine (25 mg
BID), esomeprazole (10 mg OD), and ferrous sul-
fate. Her serum creatinine was 3.6 mg/dL (baseline
2.5) with near normal serum electrolytes. The pa-
tient was stabilized and admitted to the telemetry
unit for monitoring. However, she was later found
to be confused and continued to be hypotensive
(70/40 mm Hg) and bradycardic (30 bpm) requiring
a transvenous temporary pacemaker (VVI mode,
70 bpm) at the bedside. All her home medications
were on hold and norepinephrine was initiated and
titrated to maintain her systolic blood pressure
above 100 mm Hg.
Verapamil toxicity was suspected as the likely
cause, after reviewing her medical records which
had been obtained from another hospital where she
was admitted four weeks previously for the same
reason. In addition to the aforementioned initial
management, the patient was started on insulin drip
as per the hyperinsulinemia-euglycemia therapy
(HIET) protocol [1]. The patient made a dramatic
improvement in hemodynamic status, and 24 hours
later she no longer required external pacing. With-
in 24 hours, her mental status and renal functions
had also returned to baseline and the patient was
transferred to the floor after discontinuing the in-
sulin drip. Verapamil trough level which was sent
out was reported later as elevated to 1,005 mg/L
(normal: 100–600).
The unique nature of this case, however, lies
in the ECG findings. The baseline ECG at presen-
tation revealed complete AV block with no relation
between the P wave and QRS complexes. The
P wave morphology appeared to be reflecting an ec-
topic focus, perhaps due to the sinus suppression
or perisinus tissue exit block due to drug toxicity.
Nevertheless, it was noted that with a rescue trans-
venous right ventricular apical pacing, there was an
inverted P wave with a constant VA interval indi-
cating an intact retrograde conduction (Fig. 1A).
Furthermore, review of the patient’s records
from the previous hospital showed that an electro-
physiologic study in the past for multiple admissions
for syncope had demonstrated ventriculoatrial con-
duction via the AV node without the presence of
a functional retrograde accessory pathway.
Verapamil, a calcium channel blocker which be-
longs to the sub-class of phenylalkylamines, is well
absorbed after an oral administration but undergoes
rapid biotransformation during its first pass through
the portal circulation. This results in a bioavaila
bility of 20–35% with an estimated half life of 3–
–7 hours. Verapamil is N-dealkylated in the liver to
norverapamil, which possesses 15–20% of verapam-
il’s pharmacologic activity and is subsequently
cleared renally. Complete elimination of verapamil
requires both intact hepatic and renal function [2].
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Verapamil antagonizes the L-type calcium channels
by binding to its a1 subunit and it has been shown
to significantly shorten open time and prolong
closed time of the L-type channels, rather than
change their conductance [3]. Canine experiments
studying the effect of increasing plasma verapamil
levels on both anterograde and retrograde AV node
conduction showed that both functional and effec-
tive refractory period of the AV node is increased
in a dose dependent fashion. Interestingly, the ret-
rograde conduction was found to be blocked first
with preservation of anterograde AV node conduc-
tion at plasma verapamil less than 152 ng/mL [4].
Hamer et al. [5], who studied the effect of verapamil
in humans, concluded that there are intrinsic dif-
ferences in the response of parts of the AV node to
ventricular pacing and also to the effect of verapa-
mil. It has also been demonstrated that in patients
with intact retrograde AV node conduction at base-
line, verapamil at therapeutic doses did not block
the retrograde conduction in 50% of patients [6].
The differences in responsiveness of anterograde
and retrograde AV node conduction to verapamil in
different individuals may have an association with
the patterns of distribution of the L-type calcium
channels in regions of the AV node. Our patient’s
paradoxical retrograde AV conduction, with com-
plete anterograde AV node conduction block at toxic
levels of verapamil, may explain an unusual presen-
tation or could be due to the existence of a hither-
to silent accessory or dual pathway with less
L-type channels. Elaborate animal and human stu-
dies involving molecular pharmacology and electro-
physiological models are required to understand the
complex electrical behavior of the AV node, thus
explaining this seemingly paradoxical ECG finding.
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Figure 1. Electrocardiogram rhythm strips showing lead II and lead V1; A. Preserved retrograde ventriculoatrial
conduction (note inverted p wave [arrows]) with right ventricular apical pacing; B. Return to normal sinus rhythm
after treatment.
